About | Free Trial

Last Update

2007-09-27T00:00:00.000Z

This profile was last updated on // .

Is this you? Claim your profile.

Background Information

Employment History

Chairman of the Department of Ophthalmology
Malmö University Hospital

Professor, Department of Ophthalmology
Malmö University Hospital

Professor and Chairman, Department of Ophthalmology
University of Lund , Sweden

Consultant
Carl Zeiss Meditec AG

Education

M.D.

Ph.D.

MD

PhD

Web References (27 Total References)


Glaucoma Treatment

www.tricountyeye.com [cached]

These results should be put into perspective, according to Anders Heijl, M.D., Ph.D., chairman of the Department of Ophthalmology at Sweden's Malmö University Hospital and first author of the report. "Although the study closely checked for possible glaucoma progression, many of the patients remained stable over time, even those in the control group," Dr. Heijl said. "On the other hand, despite the clear effect of treatment, glaucoma progressed in as many as 30 percent of treated patients after four years."

Dr. Heijl said that the time it took for glaucoma to progress varied greatly among patients and was sometimes rather short, even in treated patients. "This shows that in many patients with rapidly progressing glaucoma, the treatment used in this study was insufficient to halt progression of the disease," Dr. Heijl said. Dr. Heijl emphasized that treatment for early, newly diagnosed glaucoma should be individualized and carefully balanced. Before deciding on the best treatment option, eye care professionals should consider several unique patient factors, such as age, eye pressure levels, and disease severity. "The study findings support the medical community's growing contention that glaucoma treatment should be tailored to the individual needs of the patient," Dr. Heijl said.


Anders Heijl, MD, is ...

glaucomatoday.com [cached]

Anders Heijl, MD, is Professor, Department of Ophthalmology, Malmö University Hospital, Malmö, Sweden. He is the study director of the Early Manifest Glaucoma Trial, an inventor of STATPAC and GPA, and a consultant of Carl Zeiss Meditec, Inc. Dr. Heijl may be reached at +46 40 331000; anders.heijl@oftal.mas.lu.se.

...
Like Dr. Quigley, Dr. Heijl emphasized the need for more individualized treatment plans.
"We need to tailor the patient's treatment much more to the individual than we used to do," he asserted. "The data from the modern trials show that interpatient variability is tremendously large. When a patient first comes to us and we don't have follow-up data, the initial treatment should be based on intraocular pressure plus risk factors other than intraocular pressure, but later it's very important to determine the patient's individual rate of progression."
Dr. Heijl stated that software such as the recently released Humphrey Glaucoma Progression Analysis (GPA) software (Carl Zeiss Meditec, Inc.) will start to play an important role in the management of glaucoma in the next 2 to 5 years. "GPA helps you decide if the eye is stable or if [the disease] is progressing, and, if it is progressing, [GPA software] shows how fast it is progressing," commented Dr. Heijl, who went on to explain that knowing the rate of progression enables the practitioner to make the treatment decisions most suitable to the stage of disease of a particular eye (Figure 1).
...
Dr. Heijl then pointed out that the GPA software is based on 10 years of experience from the Early Manifest Glaucoma Trial and has been adapted to SITA: "The nucleus of the new GPA is glaucoma change probability maps based on pattern deviations. He explained that the GPA software flags findings on a pointwise basis when they are reproducible and prints clear text messages of possible or likely progression. The software automatically eliminates unreliable fields, he said, "which here are fields with high numbers of false-positive answers. In addition, Dr. Heijl commented that the GPA software "automatically eliminates untrained first fields, if those are out of line with the following fields.


"Clinical assessment of glaucoma ...

www.meditec.zeiss.com [cached]

"Clinical assessment of glaucoma patients, or particularly patients who have suspect glaucoma, requires assessment of visual function test results and structural parameters comparing both diagnostic modalities in each eye," said Anders Heijl, MD, PhD, Professor and Chairman, Department of Ophthalmology, University of Lund, Sweden.


Immediate Treatment Helps Delay Progression of Glaucoma [NEI News and Events]

www.nationaleyeinstitute.org [cached]

These results should be put into perspective, according to Anders Heijl, M.D., Ph.D., chairman of the Department of Ophthalmology at Sweden's Malmö University Hospital and first author of the report. "Although the study closely checked for possible glaucoma progression, many of the patients remained stable over time, even those in the control group," Dr. Heijl said. "On the other hand, despite the clear effect of treatment, glaucoma progressed in as many as 30 percent of treated patients after four years."

Dr. Heijl said that the time it took for glaucoma to progress varied greatly among patients and was sometimes rather short, even in treated patients. "This shows that in many patients with rapidly progressing glaucoma, the treatment used in this study was insufficient to halt progression of the disease," Dr. Heijl said.
Dr. Heijl emphasized that treatment for early, newly diagnosed glaucoma should be individualized and carefully balanced. Before deciding on the best treatment option, eye care professionals should consider several unique patient factors, such as age, eye pressure levels, and disease severity. "The study findings support the medical community's growing contention that glaucoma treatment should be tailored to the individual needs of the patient," Dr. Heijl said.
...
Heijl A, Leske MC, Bengtsson B, Hyman L, Bengtsson B, Hussein M, Early Manifest Glaucoma Trial Group. Reduction of Intraocular Pressure and Glaucoma Progression: Results From The Early Manifest Glaucoma Trial.


Sight & Hearing Association

www.sightandhearing.com [cached]

These results should be put into perspective, according to Anders Heijl, M.D., Ph.D., chairman of the Department of Ophthalmology at Sweden's Malmö University Hospital and first author of the report. "Although the study closely checked for possible glaucoma progression, many of the patients remained stable over time, even those in the control group," Dr. Heijl said. "On the other hand, despite the clear effect of treatment, glaucoma progressed in as many as 30 percent of treated patients after four years."

Dr. Heijl said that the time it took for glaucoma to progress varied greatly among patients and was sometimes rather short, even in treated patients. "This shows that in many patients with rapidly progressing glaucoma, the treatment used in this study was insufficient to halt progression of the disease," Dr. Heijl said.
Dr. Heijl emphasized that treatment for early, newly diagnosed glaucoma should be individualized and carefully balanced. Before deciding on the best treatment option, eye care professionals should consider several unique patient factors, such as age, eye pressure levels, and disease severity. "The study findings support the medical community's growing contention that glaucoma treatment should be tailored to the individual needs of the patient," Dr. Heijl said.

Similar Profiles

Other People with this Name

Other people with the name Heijl

Mark Heijl
Johnson Matthey Plc

David Heijl
Esko

Michael Heijl
Trygg-Hansa

Anders Heijl
Lund University

Inger van Heijl
Tergooi

Browse ZoomInfo's Business Contact Directory by City

Browse ZoomInfo's
Business People Directory

Browse ZoomInfo's
Advanced Company Directory